Clinical Trial

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. Giving acalabrutinib and rituximab may help to control mantle cell lymphoma in elderly patients.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-30 -> 2028-08-30 2026-08-08
minor Completion pushed: 2026-08-30 -> 2028-08-30 2026-08-08
Trial Details
NCT Number NCT04765111
Lead Sponsor M.D. Anderson Cancer Center
Conditions Mantle Cell Lymphoma
Enrollment 53 participants
Start Date 2021-06-30
Primary Completion 2028-08-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07